Insights: Publications Biosimilars and the Biologics Price Competition and Innovation Act (BPCIA)

LexisNexis Practical Guidance®

This article introduces biosimilars and the litigation process set up by the BPCIA to facilitate resolution of patent disputes between RPSs and biosimilar manufacturers, and touches on related trends, such as the potential use of inter partes review proceedings by biosimilar manufacturers as an alternative to or in addition to litigation.
Related Industries
If you would like to receive related insights and information from Kilpatrick Townsend, please provide your contact details by filling out the form and clicking “Agree.” If you would like to access the PDF only, please click “Download Only.”